title: Superparamagnetic nanovector with anti-cancer properties: gamma Fe2O3@Zoledronate.
abstract: We elaborate a magnetic nanovector to vectorize Zoledronate, an anti-cancer interest molecule of the hydroxmethylenebisphosphonate's family. In fact, Zoledronate is a powerful adjuvant in the treatment of bone diseases such as osteoporosis and Paget's disease. But, recent studies have shown that in addition to anti-osteoclastic properties, it presents antitumour properties notably in the case of breast and prostate cancer. However, these properties cannot be exploited due to their very high affinity to divalent cations and their preferentially accumulation in bone. To overcome this problem, one strategy is the vectorization trough maghemite nanocrystal functionalization. The specific surface coating permits to consider gamma Fe(2)O(3)@Zoledronate as a drug delivery vehicle for therapeutic activity. The anchoring to the nanoparticle's surface allowed to increase their hydrophobicity and also to change the therapeutic target, increasing the Zoledronate intestinal absorption instead of their accumulation in bone. We show that Zoledronate link the nanoparticle surface through phosphonate groups. The biological in vitro tests performed on breast cancer cell line, MDA-MB 231, showed that gamma Fe(2)O(3)@Zoledronate have antiproliferative activity. In addition, the gamma Fe(2)O(3) core could be used as MRI contrast agent for a good therapeutic evaluation.
authors.affiliation: Laboratoire CSPBAT FRE 3043 CNRS, Université Paris 13, 74 Rue Marcel Cachin, 93017 Bobigny, France.
authors.forename: Farah
authors.initials: F
authors.lastname: Benyettou
authors.forename: Yoann
authors.initials: Y
authors.lastname: Lalatonne
authors.forename: Odile
authors.initials: O
authors.lastname: Sainte-Catherine
authors.forename: Maelle
authors.initials: M
authors.lastname: Monteil
authors.forename: Laurence
authors.initials: L
authors.lastname: Motte
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry*; D045744:Cell Line, Tumor; D004164:Diphosphonates / Q000008:administration & dosage / Q000737:chemistry*; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry; D005290:Ferric Compounds / Q000008:administration & dosage / Q000737:chemistry*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000737:chemistry*; D008280:Magnetics; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D004337:Drug Carriers; D005290:Ferric Compounds; D007093:Imidazoles; D000077211:Zoledronic Acid